Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cellular transplants for Parkinson's disease].

J Guridi1, M T Herrero, M R Luquin

  • 1Departamento de Neurocirugía, Hospital de Navarra, Pamplona.

Neurologia (Barcelona, Spain)
|May 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential pathological dynamics triggered by distinct Parkinson patient-derived α-synuclein extracts in nonhuman primates.

Science advances·2025
Same author

Nigrostriatal iron accumulation in the progression of Parkinson's disease.

NPJ Parkinson's disease·2025
Same author

The mind-machine connection: adaptive information processing and new technologies promoting mental health in older adults.

The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry·2025
Same author

Visual Event-Related Potentials under External Emotional Stimuli as Early Signs for Mild Cognitive Impairment.

The journal of prevention of Alzheimer's disease·2024
Same author

Dopaminergic denervation and associated MRI microstructural changes in the nigrostriatal projection in early Parkinson's disease patients.

NPJ Parkinson's disease·2023
Same author

7-Nitroindazole reduces L-DOPA-induced dyskinesias in non-human Parkinsonian primate.

Open biology·2023

Fetal mesencephalic implants show promise for Parkinson's disease treatment in animal models and some human patients. Future research focuses on growth factors and genetically modified cells for improved efficacy and safety.

Area of Science:

  • Neuroscience
  • Regenerative Medicine
  • Cell Transplantation

Context:

  • Parkinson's disease involves the degeneration of dopaminergic neurons in the nigrostriatal pathway.
  • Animal models (rats, monkeys) with induced parkinsonism are used to test therapeutic strategies.
  • Previous studies explored implants of adrenal medulla, fetal mesencephalon, placenta, and nerve grafts.

Purpose:

  • To evaluate the efficacy of various tissue implants in restoring dopaminergic function in parkinsonian models.
  • To assess the potential of neuronal growth factors for enhancing functional recovery.
  • To review the outcomes of adrenal medulla and fetal tissue implants in Parkinson's disease patients.

Summary:

  • Fetal mesencephalic substantia nigra implants demonstrated histologic and functional viability in rat models of Parkinson's disease.

Related Experiment Videos

  • Adrenal medulla implants were effective but less sustained than fetal implants in rats.
  • In MPTP-induced parkinsonism in monkeys, fetal mesencephalic implants and other tissues showed potential benefits.
  • Human trials with adrenal medulla implants yielded a 32% improvement rate, with best candidates being those responsive to drug therapy.
  • Fetal tissue implantation in ~90 Parkinson's patients showed variable results, with moderate improvement in well-studied cases.
  • Research is exploring neuronal growth factors and genetically engineered cells for more precise and ethical Parkinson's disease treatment.

    • Impact:

    • Tissue implantation offers a potential therapeutic avenue for Parkinson's disease, though results vary.
    • Understanding striatal reinnervation factors is crucial for optimizing cell-based therapies.
    • Genetically determined cells present a future direction to overcome ethical and practical challenges associated with fetal tissue use.
    • This research informs the development of advanced Parkinson's disease treatments focusing on neurorestoration and precise biochemical correction.